Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT)
concurrently with chemotherapy was recommended for unresectable, locally advanced non …

Background: The current review aimed to pool real-world evidence on the efficacy and
toxicity of consolidation durvalumab for stage III unresectable non-small cell lung cancer …

Objectives The incidence and predictors of pneumonitis for patients with unresectable,
locally advanced non-small cell lung cancer (NSCLC) in the era of consolidation …

Background Durvalumab consolidation is associated with improved survival following
concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer …

Consolidation anti-programmed death-ligand 1 has become a new standard of care in
unresectable stage III non-small cell lung cancer (NSCLC) following chemo-radiotherapy …

Background With the widespread application of immune checkpoint inhibitor (ICI) combined
with radiotherapy (RT) for the treatment of lung cancer, increasing attention has been paid to …

Aim: We investigated the effectiveness of durvalumab post-concurrent CRT (cCRT) and post-
sequential CRT (sCRT) versus cCRT and sCRT alone and compared these outcomes with …

Sustained elevation in neutrophil‐to‐lymphocyte ratio (NLR) after initial chemoradiotherapy
(CRT) has been shown to correlate with worse prognosis in a number of solid organ …

Simple Summary The PACIFIC trial demonstrated the survival benefits of durvalumab
consolidation (DC) in patients with unresectable stage III non–small cell lung cancer …

Introduction This study aimed to investigate real-world evidence for efficacy and safety of
durvalumab consolidation (DC) after chemoradiotherapy (CRT) in patients with unresectable …